Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17591714 | 0.85 | HSD17B10 (0.49) | SMN1; SMN2L3MBTL1KMT2AMAPTPSD | |
| SCHEMBL16486803 | 0.84 | KLKB1 (0.48) | SMN1; SMN2RAB9ADUSP3L3MBTL1CYP2A6 | |
| SCHEMBL30755398 | 0.84 | LMNA (0.58) | SMN1; SMN2RAB9AKMT2ANPC1MAPT | |
| SCHEMBL1244985 | 0.83 | L3MBTL1 (0.57) | SMN1; SMN2RAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL17094867 | 0.83 | L3MBTL1 (0.50) | RAB9AL3MBTL1KMT2ANPC1CYP2A6 | |
| SCHEMBL17095073 | 0.82 | CYP3A4 (0.60) | MAPTPSDHSD17B10LMNA | |
| SCHEMBL18616337 | 0.81 | L3MBTL1 (0.59) | SMN1; SMN2RAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL18235823 | 0.80 | KMT2A (0.62) | SMN1; SMN2RAB9AL3MBTL1KMT2ANPC1 | |
| SCHEMBL20658827 | 0.80 | HSD17B10 (0.67) | SMN1; SMN2L3MBTL1KMT2AMAPTTP53 | |
| SCHEMBL19609086 | 0.80 | CA12 (0.47) | SMN1; SMN2RAB9AKMT2ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| CN-1890241-A | A2BAdenosine receptor antagonists | CV THERAPEUTICS INC (US) | 2007-01-03 | — | — | CN | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | SMN1; SMN2 3995/4885RAB9A 2087/4885DUSP3 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.